MRKR
Marker Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.20
+15.38%Oct 19, 2026, 11:00 UTC
The U.S. Food and Drug Administration awarded Marker Therapeutics a $2.6 million grant through its Orphan Products Clinical Trials grants program.
Source:Aug 21, 2026, 11:52 UTC
Marker Therapeutics filed its second-quarter 2026 10-Q with the SEC on August 14, 2026.
Source: